These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3983341)

  • 1. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.
    Bigelow LB; Kirch DG; Braun T; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Psychopharmacol Bull; 1985; 21(1):66-8. PubMed ID: 3983341
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma levels of haloperidol and clinical response.
    Van Putten T; Marder SR; May PR; Poland RE; O'Brien RP
    Psychopharmacol Bull; 1985; 21(1):69-72. PubMed ID: 3920705
    [No Abstract]   [Full Text] [Related]  

  • 3. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 9. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral prediction of response to haloperidol: a test dose strategy.
    Neborsky R; Janowsky D; Munson E; Hornbeck C; Depry D
    J Clin Psychiatry; 1982 Apr; 43(4):157-8. PubMed ID: 7068547
    [No Abstract]   [Full Text] [Related]  

  • 13. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Psychopharmacol Bull; 1988; 24(1):172-5. PubMed ID: 3387519
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of haloperidol blood level and clinical response: looking through the window.
    Volavka J; Cooper TB
    J Clin Psychopharmacol; 1987 Feb; 7(1):25-30. PubMed ID: 3546403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug holidays and serum haloperidol levels in schizophrenic patients.
    McMillan DE; Fody EP; Couch L; Harrison RH; Newton JE; Reese WG
    J Clin Psychiatry; 1986 Jul; 47(7):373-4. PubMed ID: 3722135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.